Management of severe imported malaria in adults
| Autor: | S. Jauréguiberry, A. Raffetin, L. Argaud, F. Bruneel, Philippe Corne, V. Laurent, Bruno Mourvillier, J.-F. Llitjos, Michel Wolff |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
Adult
medicine.medical_specialty medicine.medical_treatment Exchange transfusion Severity of Illness Index law.invention 03 medical and health sciences chemistry.chemical_compound law Communicable Diseases Imported parasitic diseases Health care medicine Humans Intensive care medicine Imported malaria 0303 health sciences Quinine biology 030306 microbiology business.industry Plasmodium falciparum biology.organism_classification medicine.disease Intensive care unit Malaria Infectious Diseases chemistry Artesunate Practice Guidelines as Topic business medicine.drug |
| Zdroj: | Medecine et maladies infectieuses. 50(2) |
| ISSN: | 1769-6690 |
| Popis: | Severe malaria accounts for approximately 10% of all cases of imported malaria in France; cases are mainly due to Plasmodium falciparum, while other Plasmodium species are possible but uncommon (P. vivax, P. knowlesi, P. malariae, and P. ovale). On the basis of WHO criteria for endemic areas, the French criteria defining severe imported malaria in adults have been progressively adapted to the European healthcare level. Management of severe imported malaria is a diagnostic and treatment emergency and must be initially conducted in the intensive care unit. Anti-infective treatment is now based on intravenous artesunate, which must be available in every hospital of the country likely to receive severe imported malaria patients. Intravenous quinine is thus used as a second-line treatment and is restricted to limited indications. Critical care management of organ failure is essential, particularly in patients presenting with very severe malaria. To date, no adjunctive therapy (including exchange transfusion) has demonstrated clear beneficial effects. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect